IRIS
FORCONI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.182
EU - Europa 6.693
AS - Asia 3.777
SA - Sud America 990
AF - Africa 75
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 10
Totale 24.738
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.102
GB - Regno Unito 1.669
CN - Cina 1.554
RU - Federazione Russa 1.312
IE - Irlanda 1.022
SG - Singapore 1.008
UA - Ucraina 830
BR - Brasile 821
SE - Svezia 447
HK - Hong Kong 415
FR - Francia 394
IT - Italia 351
DE - Germania 326
KR - Corea 266
VN - Vietnam 228
FI - Finlandia 179
IN - India 65
AR - Argentina 54
BD - Bangladesh 41
EC - Ecuador 38
CA - Canada 37
TR - Turchia 29
IQ - Iraq 24
AT - Austria 23
MX - Messico 23
ID - Indonesia 21
ZA - Sudafrica 21
NL - Olanda 20
PL - Polonia 20
VE - Venezuela 19
PK - Pakistan 16
UZ - Uzbekistan 16
JP - Giappone 15
PY - Paraguay 15
BE - Belgio 14
ES - Italia 14
CO - Colombia 12
SA - Arabia Saudita 12
AU - Australia 11
CL - Cile 10
EU - Europa 10
IL - Israele 10
MA - Marocco 10
CZ - Repubblica Ceca 9
HR - Croazia 9
LT - Lituania 9
GR - Grecia 8
UY - Uruguay 8
EG - Egitto 7
AE - Emirati Arabi Uniti 6
KE - Kenya 6
PE - Perù 6
TN - Tunisia 6
AL - Albania 5
AZ - Azerbaigian 5
BO - Bolivia 5
DZ - Algeria 5
JO - Giordania 5
MY - Malesia 5
BA - Bosnia-Erzegovina 4
CI - Costa d'Avorio 4
ET - Etiopia 4
IR - Iran 4
JM - Giamaica 4
LU - Lussemburgo 4
PA - Panama 4
SN - Senegal 4
TH - Thailandia 4
CH - Svizzera 3
KG - Kirghizistan 3
LV - Lettonia 3
NP - Nepal 3
OM - Oman 3
RO - Romania 3
AM - Armenia 2
AO - Angola 2
BG - Bulgaria 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
HN - Honduras 2
KZ - Kazakistan 2
MK - Macedonia 2
PH - Filippine 2
PS - Palestinian Territory 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AI - Anguilla 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GM - Gambi 1
HT - Haiti 1
Totale 24.724
Salva come PNG Salva come JPEG
Città #
Fairfield 2.212
Southend 1.488
Dallas 1.130
Ashburn 1.094
Dublin 1.018
Woodbridge 1.013
Seattle 898
Houston 783
Wilmington 763
Cambridge 732
Jacksonville 666
Chandler 566
Santa Clara 520
Singapore 519
Hong Kong 411
Moscow 410
Ann Arbor 378
Beijing 356
Seoul 264
Hefei 242
Princeton 226
Nanjing 215
Siena 204
The Dalles 117
San Diego 88
Boardman 81
Nanchang 81
Los Angeles 80
Ho Chi Minh City 78
São Paulo 72
Buffalo 65
Shenyang 61
Columbus 55
Hanoi 50
Council Bluffs 46
Redondo Beach 45
London 42
San Mateo 42
Hebei 40
New York 40
Changsha 36
Milan 36
Rio de Janeiro 34
Shanghai 33
Norwalk 32
Helsinki 31
Jiaxing 31
Dong Ket 29
Tianjin 28
Kunming 27
Flanders 25
San Francisco 25
Bengaluru 23
Falls Church 23
Menlo Park 23
Brasília 22
Düsseldorf 22
Ningbo 22
Zhengzhou 21
San Jose 20
Belo Horizonte 19
Toronto 19
Chicago 18
Hangzhou 18
Jinan 18
Nuremberg 18
Curitiba 16
Guayaquil 16
Munich 16
Warsaw 16
Brooklyn 15
Guangzhou 15
Tashkent 15
Brussels 14
Da Nang 12
Goiânia 12
Porto Alegre 12
Quito 12
Tokyo 12
Washington 12
Taizhou 11
Campinas 10
Frankfurt am Main 10
Lappeenranta 10
Phoenix 10
Dhaka 9
Fremont 9
Guarulhos 9
Haikou 9
Hounslow 9
Johannesburg 9
Manaus 9
Stockholm 9
Vienna 9
Zagreb 9
Baghdad 8
Detroit 8
Fortaleza 8
Jakarta 8
Montreal 8
Totale 18.220
Salva come PNG Salva come JPEG
Nome #
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 282
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 273
BRAF mutations in hairy-cell leukemia 266
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 265
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 263
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage 236
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 235
Overlapping morphologic and immunophenotypic profiles in small B-cell lymphoma. A report of two cases. 229
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 225
Alternative methods of cladribine administration 223
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia 222
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 221
The IGHV1-69/IGHJ3 recombinations of unmutated CLL are distinct from those of normal B cells 220
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 217
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 217
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 216
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 216
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation 211
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 207
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia 206
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 205
Emerging drugs in chronic myelogenous leukaemia 204
S1P1 expression is controlled by the pro-oxidant activity of p66Shc and is impaired in B-CLL patients with unfavorable prognosis 204
The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 204
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness 204
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 204
The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL 203
Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma 202
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 201
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 201
Towards the pharmacotherapy of hairy cell leukaemia 200
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 200
Impact of the host genetic background on prognosis of chronic lymphocytic leukemia 198
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 198
Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort 197
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 195
Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia 195
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features 195
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 195
Are surrogates of IGHV gene mutational status useful in B-cell chronic lymphocytic leukemia? The example of Septin-10 192
IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia 192
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 192
Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array 190
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation 189
Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing 189
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 189
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 188
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 188
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 188
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience 187
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 186
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia 186
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 186
MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3 185
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 185
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 185
Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis 184
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 184
Predicting the clinical course of Hodgkin lymphoma 183
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 183
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome 182
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 181
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia 180
Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia 179
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK 179
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 179
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 176
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation 175
Bcr-abl peptides for chronic myeloid leukemia. 174
Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses 173
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 172
Variant B cell receptor isotype functions differ in hairy cell leukemia with mutated BRAF and IGHV genes 172
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism 172
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 170
Origins of the malignant clone in typical Waldenstrom's macroglobulinemia 167
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 165
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance 163
IL-4 enhances expression and function of surface IgM in CLL cells 162
The Meaning and Relevance of B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia 161
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 160
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome 159
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome 159
Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition 158
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 158
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 158
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 157
Hairy cell leukaemia: biological and clinical overview from immunogenetic insights 157
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identity 155
Immunogenetics features and genomic lesions in splenic marginal zone lymphoma 154
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 154
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH 153
Three years of ibrutinib in CLL 153
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia 153
Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function 152
STING activation reverses lymphoma-mediated resistance to antibody immunotherapy 152
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch 151
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas 151
Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins. 151
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 151
Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events 150
Totale 18.914
Salva come PNG Salva come JPEG
Categoria #
all - tutte 75.207
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 75.207
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.787 0 0 0 0 0 325 138 405 277 259 222 161
2021/20221.587 110 263 52 98 71 55 86 50 89 197 168 348
2022/20232.105 158 119 312 291 224 447 34 160 243 24 59 34
2023/20241.314 68 35 68 121 33 380 457 6 7 16 9 114
2024/20253.377 91 175 222 158 461 205 73 211 276 151 316 1.038
2025/20264.821 636 1.280 880 833 1.045 147 0 0 0 0 0 0
Totale 24.890